Exelixis, Inc. (EXEL) Tacks on $23M

Exelixis, Inc. (Nasdaq: EXEL) today announced the completion of its underwritten public offering of 17,250,000 shares of its common stock, including 2,250,000 shares sold pursuant to the full exercise of an option previously granted to the underwriters to purchase additional shares. All of the shares were offered by Exelixis. Exelixis anticipates that its aggregate net proceeds from the offering will be approximately $179.4 million after deducting the underwriting discount and estimated offering expenses payable by Exelixis.

Goldman, Sachs & Co. and Cowen and Company, LLC acted as the joint book-running managers of the offering. Citi and Lazard Capital Markets LLC acted as co-managers of the offering.

The securities described above were offered by Exelixis pursuant to a shelf registration statement previously filed with the Securities and Exchange Commission (SEC), which the SEC declared effective on May 8, 2009. A final prospectus supplement related to the offering has been filed with the SEC and is available on the SEC's website located at http://www.sec.gov. Copies of the final prospectus supplement relating to the offering and accompanying prospectus forming a part of the effective registration statement may be obtained from Goldman, Sachs & Co. (200 West Street, New York, New York 10282, Attn: Prospectus Department, Phone: 1-866-471-2526, Fax: 212-902-9316, Email: [email protected] e-mail address is being protected from spambots. You need JavaScript enabled to view it ) or from Cowen and Company, LLC (c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, Phone: 631-274-2806, Fax: 631-254-7140).

This announcement does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Exelixis

Exelixis, Inc. is a biotechnology company committed to developing small molecule therapeutics for the treatment of cancer.

Suggested Articles

Data from a 10,000-patient trial showed that people with osteoarthritis taking Novartis' Ilaris had 40% to 47% lower rates of joint replacements.

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.